OBJECTIVES: Novel therapies are required for patients with recurrent or metastatic oral tongue squamous cell carcinoma (OTSCC). Fibroblast Growth Factor Receptor 1 (FGFR1) amplification frequently occurs in squamous cell carcinoma of the lung and represents a novel druggable therapeutic target in this and other malignancies. This study examined the frequency and clinical associations of FGFR1 amplification in OTSCC. MATERIALS AND METHODS: The frequency of FGFR1 amplification determined by fluorescence in situ hybridization was evaluated in a cohort of 123 OTSCC patients. Associations of FGFR1 amplification with clinical characteristics and outcome were determined. RESULTS: FGFR1 gene amplification was present in 9.3% (10/107) of cases and was significantly associated with smoking status (P = 0.03). FGFR1 amplification was seen more commonly in males (9/10 amplified cases male, P = 0.16) and there were no associations with age, stage, T stage, nodal status, alcohol history or performance status (all P>0.05). Outcome was not significantly different between FGFR1 amplified and non-amplified patients. CONCLUSIONS: Copy number variations of the FGFR1 gene occur in a subset of OTSCC with approximately 10% of cases showing amplification of the gene. FGFR1 amplification may represent a therapeutic target in OTSCC.
OBJECTIVES: Novel therapies are required for patients with recurrent or metastatic oral tongue squamous cell carcinoma (OTSCC). Fibroblast Growth Factor Receptor 1 (FGFR1) amplification frequently occurs in squamous cell carcinoma of the lung and represents a novel druggable therapeutic target in this and other malignancies. This study examined the frequency and clinical associations of FGFR1 amplification in OTSCC. MATERIALS AND METHODS: The frequency of FGFR1 amplification determined by fluorescence in situ hybridization was evaluated in a cohort of 123 OTSCC patients. Associations of FGFR1 amplification with clinical characteristics and outcome were determined. RESULTS:FGFR1 gene amplification was present in 9.3% (10/107) of cases and was significantly associated with smoking status (P = 0.03). FGFR1 amplification was seen more commonly in males (9/10 amplified cases male, P = 0.16) and there were no associations with age, stage, T stage, nodal status, alcohol history or performance status (all P>0.05). Outcome was not significantly different between FGFR1 amplified and non-amplified patients. CONCLUSIONS: Copy number variations of the FGFR1 gene occur in a subset of OTSCC with approximately 10% of cases showing amplification of the gene. FGFR1 amplification may represent a therapeutic target in OTSCC.
Authors: Friederike Göke; Alina Franzen; Trista K Hinz; Lindsay A Marek; Petros Yoon; Rakesh Sharma; Maike Bode; Anne von Maessenhausen; Brigitte Lankat-Buttgereit; Antonia Göke; Carsten Golletz; Robert Kirsten; Diana Boehm; Wenzel Vogel; Emily K Kleczko; Justin R Eagles; Fred R Hirsch; Tobias Van Bremen; Friedrich Bootz; Andreas Schroeck; Jihye Kim; Aik-Choon Tan; Antonio Jimeno; Lynn E Heasley; Sven Perner Journal: Clin Cancer Res Date: 2015-05-26 Impact factor: 12.531
Authors: Till Sebastian Clauditz; Arne Böttcher; Henning Hanken; Kerstin Borgmann; Guido Sauter; Waldemar Wilczak; Tobias Grob; Adrian Münscher Journal: J Cancer Res Clin Oncol Date: 2017-10-11 Impact factor: 4.553
Authors: Shirish M Gadgeel; Wei Chen; Michele L Cote; Aliccia Bollig-Fischer; Susan Land; Ann G Schwartz; Gerold Bepler Journal: PLoS One Date: 2013-11-08 Impact factor: 3.240
Authors: R J Young; D Urban; C Angel; J Corry; B Lyons; N Vallance; S Kleid; T A Iseli; B Solomon; D Rischin Journal: Br J Cancer Date: 2015-03-17 Impact factor: 7.640